AbbVie (NYSE:ABBV) just scored a big win for its next-generation arthritis drug. The company said Monday that Rinvoq ...
ABBV's oncology lineup, spanning blood and solid tumor drugs, faces modest Q3 growth as new launches offset Imbruvica's ...
Tuesday, October 21, 2025The Zacks Research Daily presents the best research output of our analyst team. Today's Research ...
Discover why Schwab U.S. Dividend Equity ETF™ is a top choice for stable income, strong yields, and diversification. Click ...
AbbVie said its Rinvoq showed superiority over the company’s previous bestselling drug Humira in a head-to-head trial. Results showed that 43% of patients compared to 22% of patients on Humira ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback